multiple sclerosis – media

New MS Criteria Might Show Higher False Positives

The upgraded McDonald criteria for multiple sclerosis (MS) has presented increased diagnoses in patients with clinically isolated syndrome (CIS), however a recent study of the criteria suggests that they may misguide to a number of false positive MS diagnoses in patients with a milder disease condition.
- Source: MDEdge
- 615
- August 9, 2018
clinically isolated syndrome multiple sclerosis Researches
Intermittent Fasting Could Reduce Multiple Sclerosis Symptoms

A research team from Washington University in St. Louis has been trying to investigate whether intermittent fasting could reduce multiple sclerosis symptoms, especially inflammation.
- Source: HealthLine
- 646
- August 1, 2018
multiple sclerosis Researches
Discovery of Novel Target in Multiple Sclerosis

Multiple sclerosis is a neurological disease affecting the myelin sheath that surrounds nerve fibers in the central nervous system, composed of the brain, spinal cord, and optic nerve. Since myelin is destroyed, it creates lesions which leads to an interruption in communication between the brain cells.
- Source: Medical News Today
- 634
- July 23, 2018
multiple sclerosis Researches
Novartis pads case for new MS blockbuster with disease-progression analysis

Novartis is hoping multiple sclerosis candidate siponimod’s performance in secondary progressive patients can help it secure a blockbuster approval. And now it has more data to put toward that case.
- Source: fiercepharma
- 543
- April 23, 2018
blockbuster Company Insight multiple sclerosis
Celgene shaken again after the FDA kicks back their marketing application on blockbuster hopeful ozanimod

Celgene has been slammed with a refuse-to-file letter from the FDA for ozanimod, the biggest late-stage drug it has in the pipeline.
- Source: endpts
- 684
- March 2, 2018
Celgene FDA multiple sclerosis ozanimod
Two Former Receptos Execs Launch New San Diego Biotech Startup With $100M

Gossamer Bio is launching with $100 million in seed financing and two biotech heavy hitters as leadership.
- Source: drugdu
- 485
- January 10, 2018
Crohn’s disease Market Views multiple sclerosis Series ulcerative colitis
Researchers find potential path to repair multiple sclerosis-damaged nerves

Gene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases. For multiple sclerosis, specifically, increasing cholesterol synthesis gene expression in astrocytes of the spinal cord can be a pathway to repair nerves that affect walking.
- Source: medicalxpress
- 455
- December 27, 2017
multiple sclerosis neurological Researches
Blood test offers new way to monitor disease activity

Monitoring disease activity in individuals with multiple sclerosis, either to predict flare-ups or to check treatment response, might be done with a simple blood test that measures levels of a nerve protein, according to a new study from Norway.
- Source: medicalnewstoday
- 614
- December 1, 2017
immune Market Views multiple sclerosis nerves
Study shows how gut bacteria may trigger MS

Alterations in gut bacteria at a young age could help to trigger and progress multiple sclerosis in people who are genetically predisposed to the autoimmune disease.
- Source: medicalnewstoday
- 495
- November 22, 2017
multiple sclerosis Researches
Oral Drug Beats Interferon in First Pediatric MS Trial

In the first randomized controlled trial in pediatric multiple sclerosis, fingolimod (Gilenya) significantly cut relapses compared with interferon beta-1a (Avonex), researchers reported here.
- Source: medpagetoday
- 649
- October 30, 2017
beta-1a Clinical Trials interferon multiple sclerosis pediatric

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.